Show simple item record

dc.contributor.authorRobert Sneyd, J
dc.date.accessioned2012-11-09T22:11:25Z
dc.date.accessioned2013-06-19T12:02:53Z
dc.date.accessioned2013-06-19T12:04:11Z
dc.date.available2012-11-09T22:11:25Z
dc.date.available2013-06-19T12:02:53Z
dc.date.available2013-06-19T12:04:11Z
dc.date.issued2012-10-29
dc.identifier.issn1381-6128
dc.identifier.issn1873-4286
dc.identifier.urihttp://hdl.handle.net/10026.1/1541
dc.descriptionFiles replaced (incorrect versions) on 28/7/2022 by KT (LDS).
dc.description.abstract

Etomidate is a well established intravenous anaesthetic agent which has been widely used. Recognised limitations of the agent include adrenocortical suppression, myoclonus and post-operative nausea and vomiting, PONV. MOC-etomidate, carboetomidate and MOC-carboetomidate are novel etomidate derivatives. Their preclinical data and their potential for human administration are critically reviewed. 'Soft' pharmacology (rapid ester hydrolysis) limits the duration of action of MOC-etomidate and MOC-carboetomidate giving them rapid offset after administration is discontinued. Adrenocortical depression is minimised either by ester hydrolysis or by structural change to the etomidate molecule. Potential limitations include the yet to be determined incidence of myoclonus and PONV if these new agents are administered to humans.

dc.format.extent6253-6256
dc.format.mediumPrint
dc.languageen
dc.language.isoeng
dc.publisherBentham Science Publishers Ltd.
dc.relation.replaceshttp://hdl.handle.net/10026.1/1225
dc.relation.replaces10026.1/1225
dc.relation.replaceshttp://hdl.handle.net/10026.1/1540
dc.relation.replaces10026.1/1540
dc.subjectEtomidate
dc.subjectMOC-etomidate
dc.subjectcarboetomidate
dc.subjectMOC-carboetomidate
dc.subjectpropofol
dc.subjectmidazolam
dc.titleNovel Etomidate Derivatives
dc.typejournal-article
dc.typeReview
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/22762475
plymouth.issue38
plymouth.volume18
plymouth.publisher-urlhttp://dx.doi.org/10.2174/138161212803832362
plymouth.publication-statusPublished
plymouth.journalCurrent Pharmaceutical Design
dc.identifier.doi10.2174/138161212803832362
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Users by role
dc.publisher.placeUnited Arab Emirates
dcterms.dateAccepted2012-06-28
dc.identifier.eissn1873-4286
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.2174/138161212803832362
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2012
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV